Personalis, Inc.PSNL stock score: 45/100
$14.72 · -1.74% · Scored Nov 19, 2026
- Technical
- 51
- Fundamental
- 43
- News
- —
The reading
Personalis (PSNL) scores 45 out of 100, which reads weak, higher than 34% of Healthcare stocks and 33% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 43, technicals 51.
Among the fundamentals, Revenue Quality (Quarterly) at 100 and Quick Ratio at 99 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 32 and contrarian oscillators 70 — a split worth reading before trusting the technical total.
Since Aug 22, 2026 the composite has ranged from 40 to 50, and it is down 5 points over the period.
About Personalis
Personalis (PSNL) is a U.S. genomics company focused on cancer testing. Its main clinical product is NeXT Personal, a tumor-informed molecular residual disease test that uses whole-genome sequencing of a patient’s tumor to build a personalized blood test, which then tracks tiny amounts of tumor DNA in the bloodstream to detect cancer recurrence or measure response to treatment. The test has Medicare coverage for several clinical uses, including breast cancer and immunotherapy monitoring, and Tempus AI helps sell it to oncologists under a commercial partnership. Personalis also provides genomic sequencing and analysis services to pharmaceutical and biotechnology companies for cancer drug trials and research. Customers include oncologists, cancer centers, drug developers and research institutions. Personalis earns money from clinical test reimbursement, mainly from Medicare and insurers, and from fees for biopharma services. The company has agreed to be acquired by Tempus AI, subject to shareholder and regulatory approvals.
Personalis competes with other molecular residual disease test providers, including Natera, Guardant Health and NeoGenomics. Its edge rests on a whole-genome approach designed for high sensitivity, published clinical data across several cancer types and a commercial channel through Tempus. Investors who follow PSNL stock tend to watch clinical test volumes and growth in Medicare coverage. Reimbursement rates and biopharma service revenue are closely followed. Progress toward completion of the Tempus transaction, operating losses and cash use are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward PSNL’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
43Pulling it up
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
Operating margins measure profitability after operating expenses.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
39Pulling it up
- RSI (14)100
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
- SMA 200100
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Stochastic (14) places the close within its 14-day high-low range.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 40 | 1 |
| Daily | 39 | 3 |
| Weekly | 59 | 2 |
| Monthly | 68 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 45 |
| Nov 18, 2026 | 45 |
| Nov 17, 2026 | 45 |
| Nov 16, 2026 | 45 |
| Nov 15, 2026 | 46 |
| Nov 14, 2026 | 46 |
| Nov 13, 2026 | 46 |
| Nov 12, 2026 | 40 |
| Nov 11, 2026 | 46 |
| Nov 10, 2026 | 46 |
| Nov 8, 2026 | 45 |
| Nov 7, 2026 | 45 |
| Nov 6, 2026 | 45 |
| Nov 5, 2026 | 44 |
| Nov 4, 2026 | 45 |
| Nov 3, 2026 | 46 |
| Nov 2, 2026 | 46 |
| Nov 1, 2026 | 45 |
| Oct 31, 2026 | 45 |
| Oct 30, 2026 | 45 |
| Oct 29, 2026 | 46 |
| Oct 28, 2026 | 47 |
| Oct 27, 2026 | 46 |
| Oct 26, 2026 | 46 |
| Oct 25, 2026 | 46 |
| Oct 24, 2026 | 46 |
| Oct 23, 2026 | 45 |
| Oct 22, 2026 | 46 |
| Oct 21, 2026 | 46 |
| Oct 20, 2026 | 46 |
| Oct 19, 2026 | 46 |
| Oct 18, 2026 | 44 |
| Oct 17, 2026 | 44 |
| Oct 16, 2026 | 44 |
| Oct 15, 2026 | 46 |
| Oct 14, 2026 | 46 |
| Oct 13, 2026 | 46 |
| Oct 12, 2026 | 45 |
| Oct 11, 2026 | 46 |
| Oct 10, 2026 | 46 |
| Oct 9, 2026 | 46 |
| Oct 8, 2026 | 46 |
| Oct 7, 2026 | 45 |
| Oct 6, 2026 | 46 |
| Oct 5, 2026 | 47 |
| Oct 4, 2026 | 47 |
| Oct 3, 2026 | 47 |
| Oct 2, 2026 | 47 |
| Oct 1, 2026 | 46 |
| Sep 30, 2026 | 46 |
| Sep 29, 2026 | 47 |
| Sep 28, 2026 | 46 |
| Sep 27, 2026 | 47 |
| Sep 26, 2026 | 47 |
| Sep 25, 2026 | 47 |
| Sep 24, 2026 | 49 |
| Sep 23, 2026 | 49 |
| Sep 22, 2026 | 48 |
| Sep 21, 2026 | 46 |
| Sep 20, 2026 | 47 |
| Sep 19, 2026 | 47 |
| Sep 18, 2026 | 48 |
| Sep 17, 2026 | 48 |
| Sep 16, 2026 | 47 |
| Sep 15, 2026 | 46 |
| Sep 14, 2026 | 47 |
| Sep 13, 2026 | 47 |
| Sep 12, 2026 | 47 |
| Sep 11, 2026 | 46 |
| Sep 10, 2026 | 46 |
| Sep 9, 2026 | 47 |
| Sep 8, 2026 | 49 |
| Sep 7, 2026 | 49 |
| Sep 6, 2026 | 49 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 50 |
| Sep 3, 2026 | 48 |
| Sep 2, 2026 | 48 |
| Sep 1, 2026 | 50 |
| Aug 31, 2026 | 49 |
| Aug 30, 2026 | 50 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 49 |
| Aug 27, 2026 | 48 |
| Aug 26, 2026 | 49 |
| Aug 25, 2026 | 48 |
| Aug 24, 2026 | 48 |
| Aug 23, 2026 | 50 |
| Aug 22, 2026 | 50 |
Key facts
- Market cap
- $1.6B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Beta
- 2.36
- Risk grade (1–10)
- 7
- Next earnings
- Nov 4, 2026
Diagnostics & Research peers
| Company | Market cap | Score |
|---|---|---|
| CDNA CareDx | $3.8B | 59 |
| VCYT Veracyte | $2.0B | 64 |
| NEO NeoGenomics | $2.0B | 51 |
| WGS GeneDx Holdings | $1.5B | 50 |
| OPK OPKO Health | $1.2B | 33 |
| CSTL Castle Biosciences | $1.0B | 58 |
Questions
What is PSNL's stock rating today?
PSNL scores 45/100 (Weak) as of Nov 19, 2026: technical 51, fundamental 43. Scores are recomputed every night.
What does Personalis do?
Personalis (PSNL) is a U.S. genomics company focused on cancer testing.
Is PSNL stock a buy?
The score is not a buy or sell recommendation. A 45 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the PSNL score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/psnl/"><img src="https://stocksscores.com/stocks/psnl/badge.svg" alt="PSNL stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/psnl/)